Adaptive Biotechnologies (NASDAQ: ADPT) reported Q1 EPS of ($0.29), $0.12 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $38.4 million versus the consensus estimate of $27.75 million.

“We started the year strong with revenue increasing 84% year over year, driven by growth in both our sequencing and development revenue categories,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “I am encouraged by the solid momentum across all areas of our business as we continue to capitalize on the multiple opportunities originating from our platform.”

GUIDANCE:

Adaptive Biotechnologies sees FY2021 revenue of $145-155 million.

For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.